Evolent Health's second quarter of 2026 presents one of the more uncomfortable combinations in healthcare services: revenue growing at a pace most companies would envy, and the economics of that revenue deteriorating at the same time. The company's specialty care management business, which runs clinical programs for oncology, cardiac, and other high-cost specialty treatments on behalf of health plans, generated $262.1 million of revenue in the second quarter, against managed care administration revenue of $24.3 million, and first-half total revenue reached $534.7 million against $309.5 million a year earlier. That is growth of roughly 73 percent in six months, driven by the expansion of the company's Performance Suite, the risk-based product where Evolent takes on responsibility for specialty medical claims in exchange for a fee. The top line is doing exactly what the strategy promised.
The problem is the ratio underneath. The medical expense ratio, the share of Performance Suite revenue consumed by actual medical claims, climbed to 95 percent in the first half of 2026 from roughly 85 percent a year earlier, with total claims incurred of $461.5 million against $484.5 million of Performance Suite revenue, and claims roughly doubling year over year from $214.2 million. Management attributes the deterioration to industry-wide forces that began in 2024: higher disease prevalence and higher cost per active patient, trends that other market participants have also reported. The filing is candid that these cost increases outpaced historical norms in both 2024 and 2025 and continued into the current year. When 95 cents of every Performance Suite dollar goes to claims, the margin left for Evolent's own operating costs is thin, and the product that was supposed to be the growth engine is currently running close to breakeven on a direct basis.
Why this matters for investors is that Evolent's entire investment case rests on the Performance Suite working. The company's one-segment structure means there is no other business to hide behind, and the stock's behavior shows the market has already repriced the thesis: at $4.72, Evolent trades near the bottom of a 52-week range of $2.10 to $10.08, with a market value around $534 million, a negative trailing earnings figure because the company is losing money, and a forward price-to-earnings estimate around 12 times that assumes the earnings arrive. Average volume above 3 million shares a day means the market is actively trading that question.
The strongest counterargument to the bear case is that the deterioration is industry-wide rather than Evolent-specific, and that a company with 95 percent claims ratio on a doubling revenue base is building scale that will matter when the cost trend normalizes. Specialty care is a structurally growing category as new therapies arrive, and Evolent's evidence-based clinical pathways approach is designed to steer patients toward effective, lower-cost treatment. The strongest argument for the bear case is that a risk-based product whose claims outpace pricing for two consecutive years is a product whose pricing model is broken, and that the path from 95 percent medical expense ratio to profitability requires either pricing increases that customers may resist or cost containment that the industry has not yet demonstrated. This report works through what the filing supports, what the market is pricing, and where the asymmetry lies.